{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Agent Affecting Blood or Body Fluid" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT04026438: Phase 4 Interventional Completed Complication, Postoperative
(2019)
Source URL:
First approved in 1983
Source:
NADA125961
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03504566: Phase 4 Interventional Withdrawn Diabetic Nephropathy Type 2
(2017)
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2019)
Source:
BLA761112
(2019)
Source URL:
First approved in 2019
Source:
BLA761112
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761128
(2019)
Source URL:
First approved in 2019
Source:
BLA761128
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2015)
First approved in 2015
Class:
PROTEIN
Status:
US Approved Rx
(2016)
First approved in 2015
Class:
PROTEIN
Status:
US Approved Rx
(2014)
First approved in 2014
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 2013
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 2013
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 2013
Class:
PROTEIN